B7-2 Expression above a threshold elicits anti-tumor immunity as effective as interleukin-12 and prolongs survival in murine B-cell lymphoma

International Journal of Cancer

Volumn 110, Issue 1, 2004, Pages 61-69

  Pizzoferrato, Eva ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

B7 2; Costimulatory molecules; Cytotoxic T lymphocytes; Natural cytotoxicity; Tumor immunity

Indexed keywords

CD86 ANTIGEN; INTERLEUKIN 12;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; CANCER SURVIVAL; CELL TYPE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENETIC TRANSFECTION; IMMUNE RESPONSE; IMMUNIZATION; INJECTION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TUMOR CELL; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD86; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; INTERLEUKIN-12; KILLER CELLS, NATURAL; LYMPHOMA, B-CELL; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; SURVIVAL RATE;

EID: 1942420680     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20085     Document Type: Article

References (41)

1. Schultze JL, Cardoso AA, Freeman GJ, Seamon MJ, Daley J, Pinkus GS, Gribben JG, Nadler LM. Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. PNAS 1995;92:8200-4.
2. Van Gool SW, Delabie J, Vandenberghe P, Doorevits P, De Wolf-Peters C, Ceuppens JL. Expression of B7-2 (CD86) molecules by Reed-Sternberg cells of Hodgkins' disease. Leuk 1997;11:846-51.
3. Chaperot L, Plumas J, Jacob M, Bost F, Molens J, Sotto J, Bensa J. Functional expression of CD80 and CD86 allows immunogenicity of malignant B cells from non-Hodgkin's lymphomas. Experimental Hematol 1999;27:479-88.
4. Xerri L, Devilard E, Hassoun J, Olive D, Birg F. In vivo expression of the CTLA-4 inhibitory receptor in malignant and reactive cells from human lymphomas. J Pathol 1997;183:182-7.
5. Stopeck AT, Gessner A, Miller TP, Hersh EM, Johnson CS, Cui H, Frutiger Y, Grogan TM. Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma. Clin Cancer Res 2000;6:3904-9.
6. Schultze JL. Why do B cell lymphoma fail to elicit clinically sufficient T cell immune responses? Leuk Lymphoma 1999;32:223-36.
7. Kim KJ, Kanellopoulos-Langevin C, Merwin RM, Sachs DH, Asofsky R. Establishment and characterization of BALB/c lymphoma lines with B cell properties. J Immunol 1979;122:549-54.
8. Glimcher LH, Kim KJ, Green I, Paul WE. 1a antigen-bearing B cell tumor lines can present protein antigen and alloantigen in a major histocompatibility complex-restricted fashion to antigen-reactive T cells. J Exp Med 1982;155:445-59.
9. Levitsky HI, Montgomery J, Ahmadzadeh M, Staveley-O'Carroll K, Guarnieri F, Longo DL, Kwak LW. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. J Immunol 1996;156:3858-65.
10. Pizzoferrato E, Chu RN, Hawley TS, Lieu FHL, Barber BH, Hawley RG, Watts TH, Berinstein NL. Enhanced immunogenicity of B cell lymphoma genetically engineered to express both B7-1 and interleukin-12. Human Gene Therapy 1997;8:2217-28.
11. Freeman GJ, Borriello F, Hodes RJ, Reiser H, Gribben JG, Ng JW, Kim J, Goldberg JM, Hathcock K, Laszlo G, Lombard LA, Wang S, et al. Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production. J Exp Med 1993;178:2185-92.
12. Nabavi N, Freeman G, Gaulty A, Godfrey D, Nadler L, Glimcher L. Signalling through the MHC class II cytoplasmic domain is required for antigen presentation and induces B7 expression. Nature 1992;360: 266-8.
13. Watts TH, Brian AA, Kappler JW, Marrack P, McConnell HM. Antigen presentation by supported planar membrane containing affinity purified 1-Ad. PNAS 1984;81:7564-8.
14. Ozato K, Mayer NH, Sachs DH. Monoclonal antibodies to mouse major histocompatibility complex antigens. Transplantation 1982;34: 913-20.
15. Lampson LA, Levy R. Two populations of Ia-like molecules on a human B cell line. J Immunol 1980;125:293-9.
16. Hu-Li J, Ohara J, Watson C, Tsang W, Paul WE. Derivation of a T cell line that is highly responsive to IL-4 and IL-2 (CT.4R) and of an IL-2 hyporesponsive mutant of that line (CT.4S). J Immunol 1989; 142:800-7.
17. Matzinger P. The JAM test: a simple assay for DNA fragmentation and cell death. J Immunol Methods 1991;145:185-92.
18. Chen L, Ashe S, Brady W, Hellstrom I, Hellstrom K, Ledbetter J, McGowan P, Linsley P. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992;71:1093-102.
19. Townsend S, Allison J. Tumor rejection after direct costimulation of CD8 T cells by B7-transfected melanoma cells. Science 1993;259: 368-70.
20. Yang G, Hellstrom K, Hellstrom I, Chen L. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. J Immunol 1995;154:2794-800.
21. Tsukada N, Aoki S, Maruyama S, Kishi K, Takahashi M, Aizawa Y. The heterogeneous expression of CD80, CD86 and other adhesion molecules on leukemia and lymphoma cells and their induction by interferon. J Exp Clin Cancer Res 1997;16:171-6.
22. Dorfman DM, Schultze JL, Shahsafaei A. In vivo expression of B7-1 and B7-2 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation. Blood 1997;90:4297-306.
23. Trentin L, Perin A, Siviero M, Piazza F, Facco M, Gurrieri C, Galvan S, Adami F, Agostini C, Pizzolo G, Zambello R, Semenzato G. B7 costimulatory molecules from malignant cells in patients with B-cell chronic lymphoproliferative disorders trigger T-cell proliferation. Cancer 2000;89:1259-68.
24. Chaperot L, Jacob MC, Molens JP, Manches O, Bensa JC, Plumas J. From the study of tumor cell immunogenicity to the generation of antitumor cytotoxic cells in non-Hodgkin's lymphomas. Leuk Lymphoma 2000;38:247-63.
25. Staveley-O'Carroll K, Sotomayor E, Montgomery J, Borrello I, Hwang L, Fein S, Pardoll D, Levitsky H. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci USA 1998;95:1178-83.
26. Oosterwegel MA, Greenwald RJ, Madelbrot DA, Lorsbach RB, Sharpe AH. CTLA-4 and T cell activation. Curr Opin Immunol 1999;11:294-300.
27. Linsley PS, Greene JL, Brady W, Bajorath J, Ledbetter JA, Peach R. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1994;1: 793-801.
28. Borovsky Z, Mishan-Eisenberg G, Yaniv E, Rachmilewitz J. Serial triggering of T cell receptors result in incremental accumulation of signaling intermediates. J Biol Chem 2002;277:21529-36.
29. Egen JG, Allison JP. Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity 2002;16:23-35.
30. LaBelle JL, Hanke CA, Blazar BR, Truitt RL. Negative effect of CTLA-4 on induction of T-cell immunity in vivo to B7-1+, but not B7-2+, murine myelogenous leukemia. Blood 2002;99:2146-53.
31. Zitvogel L, Robbins PD, Storkus WJ, Clarke MR, Maeurer MJ, Campbell RL, Davis CG, Tahara H, Schreiber RD, Lotze MT. Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Eur J Immunol 1996;26:1335-41.
32. Rao JB, Chamberlain RS, Bronte V, Carroll MW, Irvine K, Moss B, Rosenberg SA, Restifo NP. IL-12 Is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines. J Immunol 1996;156: 3357-65.
33. Coughlin CM, Wysocka M, Kurzawa HL, Lee WMF, Trinchieri G, Eck SL. B7-1 and interleukin 12 synergistically induce effective antitumor immunity. Cancer Res 1995;55:4980-7.
34. Geldhof AB, Raes G, Bakkus M, Devos S, Thielmans K, De Baetselier P. Expression of B7-1 by highly metastatic mouse T lymphomas induces optimal killer cell-mediated cytotoxicity. Cancer Res 1995; 55:2730-3.
35. Wu TC, Huang AY, Jaffee EM, Levistsky HI, Pardoll DM. A reassessment of the role of B7-1 expression in tumor rejection. J Exp Med 1995;182:1415-21.
36. Yeh K, Pulaski BA, Woods ML, McAdam AJ, Gaspari AA, Frelinger JG, Lord EM. B7-1 enhances natural killer cell-mediated cytotoxicity and inhibits tumor growth of a poorly immunogenic murine carcinoma. Cell Immunol 1995;165:217-24.
37. Chambers BJ, Margarita S, Ljunggren H-G. Triggering of natural killer cells by the costimulatory molecule CD80 (B7-1). Immunity 1996;5:311-7.
38. Nandi D, Gross JA, Allison JP. CD28-mediated costimulation is necessary for optimal proliferation of murine NK cells. J Immunol 1994;152:3361-9.
39. Azuma M, Cayabyab M, Buck D, Phillips JH, Lanier LL. Involvement of CD28 in MHC-unrestricted cytotoxicity mediated by a human natural killer leukemia cell line. J Immunol 1992;149:1115-23.
40. Martin-Fontecha A, Assarsson E, Carbone E, Karre K, Ljunggren H-G. Triggering of murine NK cells by CD40 and CD86 (B7-2). J Immunol 1999;162:5910-6.
41. Wilson JL, Charo J, Martin-Fontecha A, Dellabona P, Casorati G, Chambers BJ, Kiessling R, Bejarano M-T, Ljunggren H-G. NK cell triggering by the human costimulatory molecules CD80 and CD86. J Immunol 1999;163:4207-12.